NO20072851L - Hoydose forlenget frigivelses formulering av gepiron - Google Patents

Hoydose forlenget frigivelses formulering av gepiron

Info

Publication number
NO20072851L
NO20072851L NO20072851A NO20072851A NO20072851L NO 20072851 L NO20072851 L NO 20072851L NO 20072851 A NO20072851 A NO 20072851A NO 20072851 A NO20072851 A NO 20072851A NO 20072851 L NO20072851 L NO 20072851L
Authority
NO
Norway
Prior art keywords
gepirone
release formulation
present
high dose
prolonged release
Prior art date
Application number
NO20072851A
Other languages
English (en)
Inventor
Stephen J Kramer
Louis F Fabre
Original Assignee
Fabre Kramer Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fabre Kramer Holdings Inc filed Critical Fabre Kramer Holdings Inc
Publication of NO20072851L publication Critical patent/NO20072851L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår høydosering forlenget frigivelse formulering av gepiron og fremgangsmåte for behandling av tyngre depresjon ved administrering av samme til et subjekt som trenger det. Mer spesifikt angår foreliggende oppfinnelse en høydosering forlenget frigivelse tablettform av gepiron. Foreliggende oppfinnelse angår også en fremgangsmåte for behandling av depresjon hos pattedyr ved å administrere til et subjekt som trenger det en effektiv mengde av høydosering forlenget frigivelse formuleringen av gepiron ifølge foreliggende oppfinnelse.
NO20072851A 2004-11-05 2007-06-05 Hoydose forlenget frigivelses formulering av gepiron NO20072851L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/032785 WO2006052227A1 (en) 2004-11-05 2004-11-05 High-dosage extended-release formulation of gepirone

Publications (1)

Publication Number Publication Date
NO20072851L true NO20072851L (no) 2007-07-31

Family

ID=36336794

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072851A NO20072851L (no) 2004-11-05 2007-06-05 Hoydose forlenget frigivelses formulering av gepiron

Country Status (11)

Country Link
EP (1) EP1809255A4 (no)
JP (1) JP2008519071A (no)
CN (1) CN101076320A (no)
AU (1) AU2004324868B2 (no)
BR (1) BRPI0419179A (no)
CA (1) CA2585606A1 (no)
EA (1) EA013213B1 (no)
IL (1) IL182792A0 (no)
MX (1) MX2007005368A (no)
NO (1) NO20072851L (no)
WO (1) WO2006052227A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131906A1 (it) * 2013-11-18 2015-05-19 Gnosis Spa Composizioni solide orali a lento rilascio
RU2713725C1 (ru) * 2019-02-08 2020-02-06 Юрий Владимирович Соколов Биологически активная добавка и способ ее применения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
US6534507B1 (en) * 1999-12-20 2003-03-18 Fabre-Kramer Pharmaceuticals, Inc. Methods for treating psychological disorders using bioactive metabolites of gepirone
RU2003120446A (ru) * 2000-12-08 2005-02-20 Акцо Нобель Н.В. (Nl) Акцо Нобель Н.В. (Nl) Фармацевтическая форма гепирона для перорального введения
US20030220346A1 (en) * 2000-12-18 2003-11-27 Kramer Stephen J. Use of bioactive metabolites of gepirone for the treatment of psychological disorders

Also Published As

Publication number Publication date
WO2006052227A1 (en) 2006-05-18
IL182792A0 (en) 2007-08-19
MX2007005368A (es) 2007-09-11
EP1809255A4 (en) 2011-08-03
BRPI0419179A (pt) 2007-12-18
CA2585606A1 (en) 2006-05-18
AU2004324868A1 (en) 2006-05-18
EA013213B1 (ru) 2010-04-30
JP2008519071A (ja) 2008-06-05
CN101076320A (zh) 2007-11-21
EA200701010A1 (ru) 2007-10-26
AU2004324868B2 (en) 2010-04-29
EP1809255A1 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
NO20061925L (no) Farmasoytiske preparater for forebyggelse av overdose eller misbruk
NO20084256L (no) DPP IV inhibitorformuleringer
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
TW200630093A (en) Dose forms
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
NO20084826L (no) Ny administrasjonsform av racecadotril
RS52110B (en) DIPEPTIDIL PEPTIDASE INHIBITORS FOR TREATMENT OF DIABETES
AR062320A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
UA89220C2 (ru) Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
EA200970237A1 (ru) Применение тенектеплазы для лечения острого ишемического инсульта
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
CR8603A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
DK1501499T3 (da) Transepikutan indgivelsesform til behandling af restless legs-syndromet
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2006076097A3 (en) Stable non-crystalline formulation comprising losartan
AR066924A1 (es) Formulacion de nevirapina de liberacion prolongada
DK1656131T3 (da) Anvendelse af betain til behandling claudicatio intermittens
NO20072851L (no) Hoydose forlenget frigivelses formulering av gepiron
WO2005105135A8 (en) Il-6 for therapy or prevention of chemotherapy-induced neuropathy
EA200601286A1 (ru) Фармацевтические композиции, содержащие ингибитор протонового насоса и прокинетический агент
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
AR040287A1 (es) Plataforma para formulaciones transdermicas (pft)
WO2006009602A3 (en) Multiple ppi dosage form

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application